Across Asia, companies fund healthcare causes in many ways. A bank pays for a dialysis machine at a district hospital. A manufacturer sponsors a community screening day. A property developer contributes to a hospital’s patient assistance fund. A pharmaceutical company funds training for rural nurses.
When these programmes reach the annual report, they are usually described in two ways: the amount spent and a photograph of the handover. What is rarely reported is whether the machine was still in service two years later, or whether the patients helped by the fund completed their treatment. It is also rare to see whether the recipient hospital wanted the donation in the first place.
This gap matters because healthcare is not like most CSR areas. A poorly planned donation to a school library wastes money. A poorly planned donation to a hospital can absorb scarce staff time, take up storage, create disposal costs, or distort clinical practice. This article sets out a practical way for companies and recipient institutions to plan and measure healthcare CSR beyond the headline donation figure.
Healthcare CSR is distinct from employee health programmes, which are covered in our article on how employers can prove the impact of corporate wellness programmes.
Why Healthcare Giving Needs a Higher Standard
The World Health Organization has long warned that good intentions are not enough when donating to health systems.
WHO’s guidance on medical device donations was first published in 2011 and revised in a second edition in 2024. It asks donors to treat donations with the same rigour a hospital would apply when purchasing equipment. It also stresses that the intended recipient should play an active part in the decision. The updated edition sets out responsibilities for donors and recipients before, during and after a donation, and includes criteria for judging whether a donation is acceptable.
WHO’s guidelines for medicine donations follow similar principles. A donation should benefit the recipient as much as possible. It should respect the recipient’s wishes and authority. It should comply with the recipient country’s regulations and administrative arrangements. WHO also recommends that recipients keep a registry of donations received.
There is a wider reason for discipline. The WHO and World Bank UHC Global Monitoring Report 2025 found the following:
- Global health service coverage improved from 54 to 71 points on the service coverage index between 2000 and 2023.
- The share of people facing financial hardship from out-of-pocket health spending fell from 34% to 26% between 2000 and 2022.
- That hardship remains concentrated among poorer people.
- A growing number of people in middle-income countries face disproportionately high out-of-pocket costs.
Many Asian economies fall into that middle-income group. Well-targeted corporate support for patient assistance, primary care access or medicines can therefore address a real need. Poorly targeted support can simply add activity without changing access.
A Three-Level View: Inputs, Outputs and Impacts
The B4SI framework is widely used by companies to measure corporate community investment. It separates three things:
- Inputs: what the company contributes, such as cash, equipment, products, employee time and management costs.
- Outputs: what happens as a direct result, such as devices installed, patients assisted or staff trained.
- Impacts: what changes, such as shorter waiting times, services that did not previously exist, or patients who completed treatment they could not otherwise afford.
Most healthcare CSR reporting in the region stops at the first level. The donation value is an input. It shows commitment, but on its own it says nothing about benefit.
What to Measure, Programme by Programme
The right measures depend on the type of programme. The table below suggests measures for five common forms of healthcare CSR. Each recipient institution should agree the actual targets and data sources with the company.
| Programme type | Typical headline figure | Stronger output measures | Impact-level questions |
|---|---|---|---|
| Medical equipment donation | Value of equipment donated | Units installed and commissioned; staff trained to operate them; service contract and spare-parts plan confirmed | Was the equipment in service 12 and 24 months later? What services became available, and did waiting times change? |
| Medicine or consumables donation | Value of stock donated | Remaining shelf life on arrival; match with the recipient’s formulary or national essential medicines list; quantity used versus expired or destroyed | Were stock-outs avoided? Did the donation create a disposal burden for the recipient? |
| Patient financial assistance fund | Total amount disbursed | Patients assisted; time from application to approval; consistent use of published eligibility criteria | Did assisted patients start and complete the treatment the fund was intended to support? |
| Sponsored health-worker training | Number of people trained | Participants selected by the recipient institution; competency assessment results | Were skills retained at follow-up? Has practice changed, as audited by the institution? |
| Community screening or outreach partnership | Number of people screened | Proportion with abnormal results who were referred; referral completion rate | Were people with positive results linked to ongoing care? |
The last two rows overlap with issues covered in our articles on what health screening providers should measure beyond the number of people screened and how mobile clinics and outreach missions can measure more than patients seen. Companies funding these activities should expect the same follow-up questions to apply to their partnerships.
Five Questions to Answer Before a Healthcare Donation Goes Ahead
- Did the recipient ask for it? Unsolicited donations are a recurring problem in both WHO’s device guidance and its medicine guidance. A written request or needs assessment from the hospital or clinic is the most basic form of evidence that a donation is wanted.
- Can it be used, maintained and legally supplied locally? Equipment needs suitable power, consumables, trained users and service engineers. Devices and medicines must also meet the recipient country’s regulatory requirements. A donation does not exempt a product from registration rules.
- Is there a conflict of interest? Some donations create demand for the donor’s own products or influence prescribing. The clearest example is the International Code of Marketing of Breast-milk Substitutes. It rules out donations of free or subsidised breast-milk substitutes anywhere in the health system, and gifts to health workers. Companies in pharmaceuticals, medical devices and nutrition should have CSR activity reviewed against the rules that apply in their sector.
- Who owns the data? Measuring impact often requires patient-level information. That data should stay with the healthcare provider. The company should receive aggregated, anonymised reporting, handled under the applicable personal data protection law.
- What will be measured, by whom and when? Agree the baseline, the indicators, the reporting schedule and who collects the data before the handover ceremony, not afterwards.
Common Reporting Mistakes
- Using list price instead of actual cost. Reporting donated products at retail value inflates the input figure. Stating the valuation method makes the figure credible.
- Treating reach as impact. “Benefiting 10,000 people” often means 10,000 people were near an activity, not that 10,000 people were helped.
- Making health outcome claims without health outcome data. Phrases such as “saving lives” or “preventing disease” need evidence. A programme that has not measured outcomes should describe what it delivered, not what it hopes happened.
- Publicising patients without proper consent. Photographs and stories of patients who received help require informed consent and sensitivity, especially for children and people in financial distress.
- Ending at the handover. Without a follow-up review at six, 12 or 24 months, nobody knows whether the donation worked.
- Claiming system-level credit. A single donation rarely explains a change in national or district health indicators. Contribution is easier to defend than attribution.
Separating Three Kinds of Claim
Healthcare CSR communication becomes more credible when companies recognise that different statements need different evidence.
| Type of statement | Example | What it can show | Evidence needed |
|---|---|---|---|
| Input claim | “We funded a new ultrasound unit for the district hospital.” | Commitment and resources contributed | Invoices, delivery and commissioning records |
| Output or milestone claim | “The unit has been in continuous service for two years.” | Delivery, reliability, scale or duration | Hospital service logs and utilisation data, ideally confirmed by the recipient |
| Health impact claim | “The programme improved maternal health outcomes.” | A change in health status | A suitable evaluation design with comparison data, preferably conducted independently |
The first two claims are within reach of most well-run programmes. The third is much harder to support and should be used carefully.
Where Independent Recognition Fits
Some corporate healthcare programmes reach milestones that are notable because of their measurable scale or duration. Examples include a patient assistance fund that has operated continuously for many years, a training programme that has run across many sites, or an outreach partnership that has reached a documented number of communities. These are legitimate Asian business achievements. Some organisations choose to have them assessed through business awards in Asia or through record recognition in Asia.
Asia Record documents measurable achievements by businesses, organisations and institutions across the region. AsiaRecord.com is its official website. The organisation describes its verification approach as comparing a clearly defined claim with supporting evidence and the conditions under which it was measured. It also states that verification is not a popularity vote.
For companies wondering how to get an Asia Record for a healthcare CSR milestone, the measurement discipline described above is effectively the preparation:
- a precise claim;
- agreed measurement conditions;
- original records kept by both the company and the recipient institution.
Organisations that want to apply for Asia Record can review the application steps, which ask for evidence showing the achievement, how it was measured and the conditions under which it was achieved.
Two limits are important. First, becoming an Asia Record holder, or receiving any form of corporate record or company recognition in Asia, documents a measurable milestone. It does not show that a programme improved health outcomes, and it should never be presented that way. Second, people sometimes describe this process as Asia Record certification. It is not regulatory certification. It does not replace product registration for donated devices or medicines, hospital accreditation, or legal compliance in the recipient country.
Our earlier article explains what accreditation, awards and records each actually prove in healthcare.
Frequently Asked Questions
What counts as healthcare CSR?
It covers voluntary corporate contributions to health beyond a company’s core business. Common examples are donations of equipment, medicines or funds to healthcare providers, sponsored training, and partnerships with hospitals, clinics or NGOs on community health activities.
Should companies stop reporting the amount donated?
No. The amount is a legitimate input measure and is useful for transparency. It should be reported together with output measures and, where possible, impact measures, and with a clear valuation method.
Can a healthcare CSR programme be recognised as a record?
It can, if it involves a clearly defined, measurable and verifiable achievement, such as duration, scale or participation. An Asia record application is assessed against the evidence submitted. Recognition reflects the documented milestone, not the clinical value of the programme.
Who should evaluate health impact?
The recipient institution should collect patient-related data. For significant programmes, an independent evaluator such as a university public health department is better placed than the donor to judge whether health outcomes changed.
The Bottom Line
Corporate support can make a real difference to healthcare access in Asia, particularly where out-of-pocket costs remain a barrier. The test of a good programme is not the size of the cheque. It is whether the recipient wanted the support, could use it, and can show what changed as a result.
Companies that plan donations with their recipients, measure beyond the handover and describe their results precisely will produce reporting that regulators, partners and the public can trust.